As doctors and public health officials brace for a possible fall coronavirus surge, one of the challenges continues to be predicting who will have a mild, moderate or severe case of COVID-19.
Startup Curimeta Inc. emerged from stealth with $6 million in seed financing led by Washington University School of Medicine in St. Louis and BJC Healthcare, a St. Louis-based nonprofit health care system. Cultivation Capital Healthcare Innovation Fund also participated in the round.
Since its launch in the U.S. in April, Biolab Sciences Inc.’s Dermistat has facilitated the healing of 80 wounds using its unusual gel-graft formula. The product transforms a patient’s skin cells into a partial thickness skin graft in 48 hours and a full-thickness graft in five to seven days. The autologous graft material speeds recovery following surgery or burns and helps to resolve non-healing wounds.
Sichuan Jinjiang Electronic Science and Technology Co. Ltd. (JJET) recently completed series A+ and series B rounds, raising a total of ¥700 million (US$101 million) in series A and series B financing.
Founded in 2014, Bertis Co. Ltd. is developing proteomics-based diagnostics and biomarkers by combining artificial intelligence/machine learning (AI/ML) algorithms with high-performance mass spectrometry technology. Using this technology, it is able to quantify extremely small amounts of protein.
Heartpoint Global Inc. has reached a milestone in the ongoing preclinical trials of its Heartpoint Global Implant System (HPGS), focused on treating left heart diseases, congestive heart failure, and structural pulmonary hypertension. In large animal studies, the system appeared to significantly improve the structure of the heart and the function of the heart-lung system.
South Korea’s Medipost Co. Ltd. is gearing up for phase III trials in the U.S. of its stem cell therapy, Cartistem, an allogeneic human umbilical cord blood-derived mesenchymal stem cell therapy for treatment of knee articular damage in patients with osteoarthritis.
The Royal Academy of Engineering in the U.K. is supporting another batch of health care innovations in developing countries, which range from surgical robots to tissue regeneration material. A number of entrepreneurs supported by the Academy’s Leaders in Innovation Fellowships (LIF) Global 2022 program were recently given the additional opportunity to secure further expert mentoring from engineers from the Academy's network and join a peer network of U.K. founders.
Clarity Pharmaceuticals Ltd. is progressing three of its targeted copper theranostics through the clinic that are based on its sarcophagine technology that securely holds copper isotopes inside a cage-like structure, called a chelator. The SAR technology allows a unique pairing of copper isotopes, copper-64 and copper-67, for both cancer diagnosis and therapy.
A technology developed at the University of Birmingham, U.K., has been spun off as a potential treatment for ocular surface diseases. The platform technology from startup Healome Therapeutics Ltd. was developed by a team of material scientists at the University’s Healthcare Technologies Institute (HTI) that translates health technology concepts to products for clinical trials.
RSS
